disease

msa

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about msa: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

11Connections
0Hypotheses
0Analyses
5Outgoing
6Incoming

No summary available yet. View on Wiki →

Disease Info
Phase 1/2 focusMajority of trials in early phases, limited Phase 3 activity
Synuclein targetingMultiple programs targeting alpha-synuclein aggregation or propagation
Neuroprotective approachesBroad-spectrum neuroprotection given rapid progression
Symptomatic trialsAutonomic dysfunction management (orthostatic hypotension, urinary dysfunction)
Alpha-synuclein modulationPrograms from biotech companies targeting alpha-synuclein aggregation
NeuroprotectionPreserving autonomic and motor neurons given rapid progression
Autonomic dysfunctionOrthostatic hypotension, bladder/bowel dysfunction primary causes of morbidity
Myelin protectionOligodendrocyte dysfunction is central to MSA pathology
Biomarker developmentNeurofilament light chain (NfL), alpha-synuclein seed amplification assays
Rapid progressionShorter window for intervention than PD or AD
Diagnostic delayAverage 3-5 years from symptom onset to diagnosis
HeterogeneityMSA-P vs MSA-C phenotypes complicate trial design
DatabasesOMIMOrphanetClinicalTrialsPubMed

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

msa

general · 918 words

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

therapeutic · 15794 words

Clinical Management Guide for CBS/PSP

therapeutic · 15224 words

Progressive Supranuclear Palsy (PSP)

disease · 12907 words

Novel Therapy Index

idea · 10647 words

CBS/PSP Supplements Guide

therapeutic · 6929 words

Pathway Diagram

flowchart TD
    N0["MSA"]
    N1["synucleinopathies"]
    N0 -->|"contributes to"| N1
    N2["alpha_synuclein"]
    N2 -->|"causes"| N0
    N3["NEURODEGENERATION"]
    N0 -->|"associated with"| N3
    N4["SCHIZOPHRENIA"]
    N0 -->|"associated with"| N4
    N5["HAND"]
    N5 -->|"associated with"| N0
    N6["ALS"]
    N6 -->|"associated with"| N0
    N7["AUTISM"]
    N7 -->|"associated with"| N0
    N8["DEPRESSION"]
    N8 -->|"associated with"| N0
    N9["EPILEPSY"]
    N9 -->|"associated with"| N0
    N10["PARKINSON"]
    N0 -->|"co discussed"| N10
    N11["PARKINSON'S"]
    N0 -->|"co discussed"| N11

    classDef gene fill:#1a3a2a,stroke:#4caf50,color:#e0e0e0
    classDef protein fill:#1a2a3a,stroke:#4fc3f7,color:#e0e0e0
    classDef disease fill:#3a1a1a,stroke:#ef5350,color:#e0e0e0
    classDef pathway fill:#2a1a3a,stroke:#ce93d8,color:#e0e0e0
    classDef mechanism fill:#2a2a1a,stroke:#ffd54f,color:#e0e0e0
    classDef therapeutic fill:#1a2a2a,stroke:#26a69a,color:#e0e0e0
    class N1 disease
    class N2 protein

Outgoing (5)

TargetRelationTypeStr
synucleinopathiescontributes_todisease0.76
NEURODEGENERATIONassociated_withentity0.60
SCHIZOPHRENIAassociated_withentity0.60
PARKINSONco_discussedentity0.50
PARKINSON'Sco_discussedentity0.50

Incoming (6)

SourceRelationTypeStr
alpha_synucleincausesprotein0.72
HANDassociated_withentity0.60
ALSassociated_withentity0.60
AUTISMassociated_withentity0.60
DEPRESSIONassociated_withentity0.60

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found